Literature DB >> 4083862

Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

J M Trang, R F Jacobs, G L Kearns, A L Brown, T G Wells, F L Underwood, R B Kluza.   

Abstract

The pharmacokinetics and cerebrospinal fluid (CSF) penetration of cefotaxime (Ctx) and desacetylcefotaxime (dCtx) were evaluated in 13 infants and children with meningitis after dose 6 of Ctx in a multiple-dose intermittent intravenous infusion regimen (50 mg/kg every 6 h). Model-dependent and noncompartmental pharmacokinetic parameters were determined and were found to be congruous. The disposition of both Ctx and dCtx was described adequately by a one-compartment, open model. Noncompartmental pharmacokinetic parameters are reported. The mean Ctx serum concentration at 0.25 h postinfusion was 121.2 micrograms/ml, and the mean CSF concentration at 1 h postinfusion was 6.2 micrograms/ml. The CSF/serum ratio was variable (0 to 20%), with a mean penetration of 10.1%. The mean Ctx elimination half-life, apparent steady-state volume of distribution, and total body clearance were 0.8 h, 0.361 liter/kg, and 0.289 liter/h per kg, respectively. For Ctx, 61% of the dose was excreted unchanged in the urine during the 6-h postinfusion period, and the estimated renal clearance was 0.174 liter/h per kg. No significant correlations were observed between Ctx pharmacokinetic parameters and demographic parameters. The mean peak concentration of dCtx in serum (21.6 micrograms/ml) occurred at approximately 1.5 h postinfusion, and the mean concentration in CSF at 1 h postinfusion was 5.6 micrograms/ml. The CSF/serum ratio was extremely variable (0 to 103%), and the mean penetration was 28.8%. The mean apparent elimination half-life for dCtx was 2.1 h. In infants and children with normal renal function, a 50-mg/kg dose of Ctx administered every 6 h should provide adequate concentrations in serum and CSF in the majority of patients with meningitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4083862      PMCID: PMC180330          DOI: 10.1128/AAC.28.6.791

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Computation of model-independent pharmacokinetic parameters during multiple dosing.

Authors:  L A Bauer; M Gibaldi
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

2.  Cefotaxime in serious infections--a clinical and pharmacokinetic study.

Authors:  T Kalager; A Digranes; K Bakke; K B Hellum; T Bergan; C O Solberg
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

3.  Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.

Authors:  M Ohkawa; A Okasho; I Motoi; S Tokunaga; R Shoda; S Kawaguchi; M Sawaki; M Shimamura; S Hirano; K Kuroda; S Awazu
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

4.  Pharmacokinetics of cefotaxime in newborn infants.

Authors:  G H McCracken; N E Threlkeld; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

5.  A microcomputer program in Basic for iterative, non-linear data-fitting to pharmacokinetic functions.

Authors:  F Nielsen-Kudsk
Journal:  Int J Biomed Comput       Date:  1983-03

6.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.

Authors:  R M Ings; J P Fillastre; M Godin; A Leroy; G Humbert
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

7.  Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

9.  Clinical pharmacology of cefotaxime in pediatric patients.

Authors:  D A Kafetzis; D C Brater; J Kanarios; C A Sinaniotis; C J Papadatos
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

10.  Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.

Authors:  R Wise; N Wright; P J Wills
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

View more
  29 in total

1.  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.

Authors:  Maurice J Ahsman; Enno D Wildschut; Dick Tibboel; Ron A Mathot
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high-dosage cefotaxime.

Authors:  I R Friedland; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury.

Authors:  Claire Dahyot-Fizelier; Denis Frasca; Nicolas Grégoire; Christophe Adier; Olivier Mimoz; Bertrand Debaene; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

4.  Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.

Authors:  M E Falagas; L McDermott; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Bactericidal activity against intermediately cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with bacterial meningitis treated with high doses of cefotaxime and vancomycin.

Authors:  C Doit; J Barre; R Cohen; S Bonacorsi; A Bourrillon; E H Bingen
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 6.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

7.  Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections.

Authors:  R F Jacobs; S L Kaplan; G E Schutze; A S Dajani; R J Leggiadro; C S Rim; S K Puri
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.

Authors:  Elsa Maksoud; Berengere Koehl; Aude Facchin; Phuong Ha; Wei Zhao; Florentia Kaguelidou; Malika Benkerrou; Patricia Mariani; Albert Faye; Mathie Lorrot; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

10.  Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.

Authors:  C M Paap; M C Nahata; M A Mentser; J D Mahan; S K Puri; J W Hubbard
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.